Get startedLog in
    Picture of Johnson & Johnson logo

    JNJ — Johnson & Johnson News Story

    0.000.00%
    us flag iconLast trade - 00:00
    HealthcareConservativeLarge CapHigh Flyer
    All News

    Brief: J&J Says Rybrevant Plus Chemotherapy Delivers Longest Reported Median Overall Survival In EGFR Exon 20 Insertion NSCLC

    Picture of Johnson & Johnson logoJohnson & Johnson
    14/09/2026 02:47
    BRIEF-J&J Says Rybrevant Plus Chemotherapy Delivers Longest Reported Median Overall Survival In EGFR Exon 20 Insertion NSCLC
    Sept 13 (Reuters) - Johnson & Johnson JNJ.N:
    • J&J - RYBREVANT PLUS CHEMOTHERAPY DELIVERS LONGEST REPORTED MEDIAN OVERALL SURVIVAL IN EGFR EXON 20 INSERTION NSCLC
    Source text: ID:nPnbt1YV1a
    Further company coverage: JNJ.N

     ((Reuters.Briefs@thomsonreuters.com;))

    Recent news on Johnson & Johnson

    See all news